1760P COVID-19 severe pneumonia in cancer patients: Impact and predictive factors

Abstract

Background: Representatives from 8 global cancer coalitions/alliances, representing 650 cancer patient groups and the interests of over 14 million patients have come together during the pandemic to review and evaluate the patient-perspective impact. Cancer services have faced challenges as a result of COVID-19, including suspension of screening and diagnostic services; delays in diagnosis leading to higher mortality rates; cancellation/deferral of life-saving treatments; changes in treatment regimens and suspension of vital research. For organisations that provide support to cancer patients, declining income, the need to reduce staff and move to virtual working practices has put extra strain while demand for support due to the pandemic has increased.Methods: 5 coalitions surveyed their member organisations. A number of coalitions consulted their members by individual surveys or consultations.

Assessment of Clinical Indicators Registered on Admission to the Hospital Related to Mortality Risk in Cancer Patients with COVID-19

“…We calculated that the presence of such symptoms on admission doubles the risk of death in our cancer patients, and the generated curve shows a lower survival chance in this COVID-19 patient group (Figure 3). The literature confirms that severe pneumonia is frequent in cancer patients with COVID-19 and leads to high mortality [26]. Although rales are considered the most common symptom at chest auscultation in COVID-19 patients [27] and were identified in 26 oncology patients (Table S2), they were not a variable affecting the risk of death (p = 0.709).…”

“…Although rales are considered the most common symptom at chest auscultation in COVID-19 patients [27] and were identified in 26 oncology patients (Table S2), they were not a variable affecting the risk of death (p = 0.709). Lung tumors are considered a risk factor for developing this condition [26]. A recent updated study of survival in patients with COVID-19 disease and lung cancer, which included more than 21,000 patients, found that lung cancer modifies COVID-19 prognosis in terms of disease progression and mortality [28].…”